BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
June 2, 2006
View Archived Issues
Cangene Gets $362M Contract Under BioShield For Botulism
The U.S. government has contracted with the Canadian firm Cangene Corp. on a $362 million agreement for a botulism treatment, the first award for that potential bioterror agent. (BioWorld Today)
Read More
Proteolix Series B: $45M To Boost Proteasome Program
Read More
New Research Helps Explain Neurology Drug Mechanisms
Read More
Ambion Spin-Off Asuragen Brings In $49M Via Series A
Read More
Other News To Note
Read More
Clinic Roundup
Read More